AOFAS Podcast MasterClass: Ankle Instability
Statement of Need
A need for this educational activity has been determined based on previous course evaluations and the AOFAS educational curriculum. The content of this course was based on current issues and topics provided by AOFAS membership and leadership. For more information on the AOFAS CME mission, visit aofas.org/education.
Accreditation
The American Orthopaedic Foot & Ankle Society (AOFAS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
Disclaimer
The material presented in this continuing medical education activity has been made available by the American Orthopaedic Foot & Ankle Society (AOFAS) for educational purposes only. This material is not intended to represent the only, nor necessarily the best, methods or procedures appropriate for the medical situation discussed, but rather is intended to present an approach, view, statement, or opinion of the authors or presenters, which may be helpful or of interest to other practitioners. Methods, techniques, and procedures demonstrated and views and opinions expressed by speakers, presenters, and faculty are their own, and do not necessarily represent those of AOFAS, nor does presentation on the program represent or constitute endorsement or promotion by AOFAS. AOFAS expressly disclaims any warranties or guarantees, expressed or implied, and shall not be liable for damages of any kind in connection with the material, methods, information, techniques, opinions, or procedures expressed, presented, or demonstrated.
Disclosure of Conflict of Interest
Disclosure Statement
AOFAS mandates all instructors, planners, and other individuals in a position to control or influence the content of an educational activity to disclose all financial relationships that you have had in the past 24 months with ineligible companies. An "ineligible company" is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All identified conflicts must be mitigated, and the education content vetted by the AOFAS for fair balance, scientific objectivity, and appropriateness. All disclosures will be provided in this final program distributed at the meeting to all program participants.
FDA Statement
Some drugs or medical devices demonstrated at this meeting have not been cleared by the FDA or have been cleared by the FDA for specific purposes only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical devices he or she wishes to use in clinical practice. AOFAS policy provides that "off label" uses of a drug or medical device may be described in its CME activities so long as the "off label" use of the drug or medical device is also specifically disclosed (i.e., it must be disclosed that the FDA has not cleared the drug or device for the described purpose). Any drug or medical device is being used "off label" if the described use is not set forth on the products approval label.
Faculty/Planner Disclosure Declaration
As an Accreditation Council for Continuing Medical Education (ACCME) provider, AOFAS has the obligation to ensure the delivery of education that is balanced and free of commercial bias. To achieve this, it is the policy of the AOFAS that all CME-related Board, committee members ("planners"), faculty, and appropriate staff disclose in writing to the learners all financial relationships that you have had in the past 24 months with ineligible companies. An "ineligible company" is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In addition to faculty members, commentators from the floor are charged with verbally disclosing any interests immediately prior to speaking. All disclosures are provided in this final program distributed at the meeting to all program participants.
In accordance with AOFAS policy:
Faculty participation in this educational activity will be predicated upon timely submission and review of AOFAS disclosure. An individual who refuses to disclose relevant financial relationships will be disqualified from being a planning committee member, a teacher, or an author of CME, and cannot have control of, or responsibility for, the development, management, presentation, or evaluation of the CME activity. Non-compliance will result in a faculty member being stricken from the program.
An indication of the participant's disclosure appears after his or her name as well as the commercial company or institution that provided the support. AOFAS does not view the existence of these disclosed interests or commitments as necessarily implying bias or decreasing the value of the author's participation in this activity. In addition to ensuring that presentations be free of bias, faculty members are required to ensure that all material presented and discussed will be based on best-available evidence.
Disclosure Statement
AOFAS mandates all instructors, planners, and other individuals in a position to control or influence the content of an educational activity to disclose all financial relationships that you have had in the past 24 months with ineligible companies. An “ineligible company” are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients
All identified conflicts must be mitigated, and the education content vetted by the AOFAS for fair balance, scientific objectivity, and appropriateness. All disclosures will be provided in this final program distributed at the meeting to all program participants.
FDA Statement
Some drugs or medical devices demonstrated at this meeting have not been cleared by the FDA or have been cleared by the FDA for specific purposes only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical devices he or she wishes to use in clinical practice. AOFAS policy provides that “off label” uses of a drug or medical device may be described in its CME activities so long as the “off label” use of the drug or medical device is also specifically disclosed (i.e., it must be disclosed that the FDA has not cleared the drug or device for the described purpose). Any drug or medical device is being used “off label” if the described use is not set forth on the products approval label.
Faculty/Planner Disclosure Declaration
As an Accreditation Council for Continuing Medical Education (ACCME) provider, AOFAS has the obligation to ensure the delivery of education that is balanced and free of commercial bias. To achieve this, it is the policy of the AOFAS that all CME-related board members, committee members (“planners”), faculty, and appropriate staff disclose in writing to the learners’ all financial relationships that you have had in the past 24 months with ineligible companies. An “ineligible company” are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In addition to faculty members, commentators from the floor are charged with verbally disclosing any interests immediately prior to speaking. All disclosures are provided in this final program distributed at the meeting to all program participants.
In accordance with AOFAS policy:
Faculty participation in this educational activity will be predicated upon timely submission and review of AOFAS disclosure. An individual who refuses to disclose all financial relationships will be disqualified from being a planning committee member, a teacher, or an author of CME, and cannot have control of, or responsibility for, the development, management, presentation, or evaluation of the CME activity. Non-compliance will result in a faculty member being stricken from the program.
An indication of the participant’s disclosure appears after his or her name as well as the ineligible company that provided the support. AOFAS does not view the existence of these disclosed interests or commitments as necessarily implying bias or decreasing the value of the author’s participation in this activity. In addition to ensuring that presentations be free of bias, faculty members are required to ensure that all material presented and discussed will be based on best- available evidence.
Podcast Faculty Disclosures
Eric I. Ferkel, MD
Arthrex Inc.: Speakers' Bureau
DePuy Synthes: Paid Consultant
Ferring: Paid Consultant
Medartis: Paid Consultant
Ossio: Paid Consultant
Smith & Nephew: Paid Consultant
Anish R. Kadakia, MD
Acumed: Royalties
Arthrex Inc.: Paid Consultant, Royalties, Speakers' Bureau
elsevier: Royalties - Publisher
Johnson & Johnson: Royalties
Peter Mangone, MD
Artelon: Paid Consultant, Speakers' Bureau
Arthrex, Inc: Royalties
Osteocentric: Paid Consultant, Stock or stock options
Stryker: Employee, Paid Consultant, Royalties, Speakers' Bureau
Vilex, LLC: Paid Consultant
Ziptek: Paid Consultant, Speakers' Bureau
Ziptek: Stock or stock options
Nicholas L. Strasser, MD
Wright/Stryker medical: Grant/Research Support
OnDemand Education Committee Disclosures (Planners)
Nasef Mohamed N Abdelatif PhD, MD
Arthrex Inc.: Paid Consultant
Timothy Charlton MD
Extremity Medical: Royalties
Matthew S. Conti MD
Nothing to Disclose
M. Truitt Cooper MD
GLW: Stock-privately held company
In2Bones: Paid Consultant, Royalties
Smith & Nephew: Grant/Research Support
Stryker: Educational Grant
Cesar de Cesar Netto MD, PhD
AAOS: Board member/Committee Member
AOFAS: Board member/Committee Member
Artelon: Paid Consultant, Royalties
CurveBeam: Paid Consultant, Stock or stock options
Foot & Ankle International: Editorial/Governing board - Publications
Foot and Ankle Clinics: Editorial/Governing board - Publications
International WBCT Society: Board member/Committee Member
Medartis: Paid Consultant, Royalties
Paragon 28: Grant/Research Support, Paid Consultant, Royalties
Stryker: Paid Consultant
Tayco Brace: Stock-privately held company
Zimmer-Biomet: Paid Consultant, Royalties
Tyler Gonzalez MD, MBA
DJO: Paid Consultant
Exactech: Paid Consultant
Stryker: Paid Consultant
Treace Medical Concepts Inc: Paid Consultant
Adam T. Groth MD
Nothing to Disclose
Mark Hagy MD
Nothing to Disclose
Kurt Hofmann MD
AOFAS: Board member/Committee Member
Centric Medical: Paid Consultant
Globus Medical: Paid Consultant
Isto: Grant/Research Support
Anny Hsu MD
Nothing to Disclose
J. Benjamin Jackson MD, MBA
Nothing to Disclose
Anish R. Kadakia MD
Acumed: Royalties
Arthrex Inc.: Paid Consultant, Royalties, Speakers' Bureau
elsevier: Royalties - Publisher
Johnson & Johnson: Royalties
Kristin L. Kress MD
Nothing to Disclose
Wonyong Lee MD
Nothing to Disclose
Christopher P. Miller MD
Arthrex, Inc: Grant/Research Support, Paid Consultant, Speakers' Bureau
Pradeep Moonot FRCS, MRCS, MS
Nothing to Disclose
Joseph Park MD
American Orthopaedic Foot and Ankle Society: Board member/Committee Member
DePuy A Johnson & Johnson Company: Grant/Research Support, Paid Consultant, Speakers' Bureau
Integra LifeSciences: Grant/Research Support, Royalties - Publisher
LifeNet Health: Paid Consultant
Saunders/Mosby-Elsevier: Royalties - Publisher
Rachel Shakked MD
Arthrex Inc.: Speakers' Bureau
W. Bret Smith DO
Nothing to Disclose
Nicholas L. Strasser MD
Wright/Stryker medical: Grant/Research Support
Eric W. Tan MD
Arthrex Inc.: Paid Consultant, Speakers' Bureau
Red Point Medical: Paid Consultant, Stock-privately held company
Stryker: Paid Consultant, Speakers' Bureau
All of the relevant financial relationships listed for these individuals have been mitigated.